Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review Publisher Pubmed



Rahaviezabadi S1 ; Zhou S2 ; Lee SE3 ; Ference E4 ; Magit A5, 6 ; Leuin S5, 6 ; Mohamed K7, 8 ; Rezaei N9, 10 ; Patel VA5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Otorhinolaryngology–Head and Neck Surgery, Otorhinolaryngology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. USC Caruso Department of Otolaryngology–Head and Neck Surgery, Los Angeles, CA, United States
  3. 3. Division of Otolaryngology–Head and Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  4. 4. Department of Otolaryngology, Facey Medical Group, Los Angeles, CA, United States
  5. 5. Department of Otolaryngology–Head and Neck Surgery, University of California San Diego, La Jolla, CA, United States
  6. 6. Division of Pediatric Otolaryngology, Rady Children's Hospital–San Diego, San Diego, CA, United States
  7. 7. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Network of Empirical, Gustatory, and Olfactory Aesthetics (NEGOA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  9. 9. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  10. 10. Network of Immunity in Infection Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Otolaryngology - Head and Neck Surgery (United States) Published:2024


Abstract

Objective: Provide clinicians with current evidence for biologic therapy in children with chronic rhinosinusitis with nasal polyposis (CRSwNP). Data Sources: PubMed, MEDLINE, Cochrane, and clinical trial registries. Review Methods: Key search terms related to biologic therapy in pediatric CRSwNP were identified via a structured query of current medical literature and clinical trial databases. Conclusions: There is a dearth of active clinical trials and research studies for biologics targeting pediatric CRSwNP. There is an ongoing compassionate-use clinical trial involving Dupilumab for children with nasal polyps as well as only 1 published work specifically focused on Dupilumab for pediatric CRSwNP in the setting of aspirin-exacerbated respiratory disease. Implications for Practice: For children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease. © 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.